Characterization of a fit-for-purpose commercial rapid mycoplasma PCR test solution for routine quality control

Cell & Gene Therapy Insights 2022; 8(1), 1;


Published: 3 February 2022
Jessica Hutcheson

Watch the video or read the poster to learn about

  • Why mycoplasma contamination poses a significant safety and economic risk to biopharmaceutical manufacturers
  • Nucleic acid amplification technique (NAT)-based assays as rapid, sensitive, and reproducible alternatives to direct agar culture
  • How fast and accurate mycoplasma detection can support the evolving needs of cell and gene therapy developers through commercial manufacturing

Jessica Hutcheson over the last decade, has gained extensive involvement in working within several labs focusing on regenerative medicine. With years of lab management experience in the biotech industry and academia, she has developed skills for coordinating and managing a team throughout small- and large-scale projects. Alongside her project management, Jessica has gained skillsets in mammalian cell culture (including a primary cell, stem cell, and induced Pluripotent stem cells), and molecular biology techniques. At Rubhu Biologics she plans to continue to provide both research and administrative support to the company.